169 related articles for article (PubMed ID: 33545802)
61. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Ando Y; Kawaoka T; Suehiro Y; Yamaoka K; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Azakami T; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2020; 98(11):787-797. PubMed ID: 32882687
[TBL] [Abstract][Full Text] [Related]
62. [A case of advanced gastric cancer with obstructive jaundice due to multiple liver metastasis successfully treated with the following combination therapy of CPT-11 and cisplatin after combination therapy of paclitaxel and TS-1].
Watanabe T; Uchida M; Harada K; Homma N; Ogata N; Funada R; Hasegawa K; Soga K; Shibasaki K
Gan To Kagaku Ryoho; 2007 Apr; 34(4):605-8. PubMed ID: 17431349
[TBL] [Abstract][Full Text] [Related]
63. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
[TBL] [Abstract][Full Text] [Related]
64. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
[TBL] [Abstract][Full Text] [Related]
65. [Radiofrequency ablation combined with transcatheter arterial chemoembolization for the local recurrent tumor after resection of the adrenal metastasis from hepatocellular carcinoma--a case report].
Yasumoto T; Hayashi S; Shimizu J; Dono K; Nakata S; Sato M; Kitada M; Shimano T
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2371-3. PubMed ID: 20037426
[TBL] [Abstract][Full Text] [Related]
66. A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1.
Nakamura R; Saikawa Y; Kumagai K; Kiyota T; Ohashi M; Yoshida M; Kubota T; Kumai K; Kitajima M
Int J Clin Oncol; 2007 Aug; 12(4):295-9. PubMed ID: 17701010
[TBL] [Abstract][Full Text] [Related]
67. [A case of advanced hepatocellular carcinoma with inferior vena cava tumor thrombus and multiple intrahepatic metastases treated successfully by transcatheter arterial chemoembolization and radical hepatectomy].
Yamanaka C; Wada H; Hama N; Kobayashi S; Akita H; Kawamoto K; Marubashi S; Eguchi H; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1819-21. PubMed ID: 23267897
[TBL] [Abstract][Full Text] [Related]
68. [A case of long-term survival after undergoing S-1 based multidisciplinary therapy for liver metastasis of gastric cancer].
Ito G; Kubo N; Tanaka H; Muguruma K; Sakurai K; Kimura K; Nagahara H; Noda E; Amano R; Yamada N; Yashiro M; Maeda K; Sawada T; Nakata B; Ohira M; Hirakawa K
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2348-50. PubMed ID: 22202378
[TBL] [Abstract][Full Text] [Related]
69. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.
Koizumi Y; Hirooka M; Hiraoka A; Ochi H; Tanaka T; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Miyake T; Matsuura B; Michitaka K; Joko K; Abe M; Hiasa Y
Endocr J; 2019 Sep; 66(9):787-792. PubMed ID: 31142692
[TBL] [Abstract][Full Text] [Related]
70. Hemorrhagic Gastric Metastasis from Hepatocellular Carcinoma Successfully Treated Using Coil Embolization of the Left Gastric Artery.
Imai M; Ishikawa T; Okoshi M; Tomiyoshi K; Kojima Y; Horigome R; Nozawa Y; Sano T; Iwanaga A; Honma T; Nemoto T; Takeda K; Nishikura K; Ishihara N; Yoshida T
Intern Med; 2019 Aug; 58(15):2179-2183. PubMed ID: 30996163
[TBL] [Abstract][Full Text] [Related]
71. Early Improvement of Non-islet Cell Tumor Hypoglycemia by Chemotherapy Using Lenvatinib in a Case with Type 2 Diabetes and Hepatocellular Carcinoma Producing Big IGF-II.
Izutsu T; Ito H; Fukuda I; Tamura H; Matsumoto S; Antoku S; Mori T; Goto H
Intern Med; 2021 May; 60(9):1427-1432. PubMed ID: 33250459
[TBL] [Abstract][Full Text] [Related]
72. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
[TBL] [Abstract][Full Text] [Related]
73. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
74. Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma.
Meng M; Li W; Yang X; Huang G; Wei Z; Ni Y; Han X; Wang J; Ye X
J Cancer Res Ther; 2020; 16(2):327-334. PubMed ID: 32474520
[TBL] [Abstract][Full Text] [Related]
75. Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma.
Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Matsuura B; Joko K; Michitaka K; Abe M; Hiasa Y
Intern Med; 2019 Mar; 58(6):791-795. PubMed ID: 30333428
[TBL] [Abstract][Full Text] [Related]
76. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting.
Obi S; Sato T; Sato S; Kanda M; Tokudome Y; Kojima Y; Suzuki Y; Hosoda K; Kawai T; Kondo Y; Isomura Y; Ohyama H; Nakagomi K; Ashizawa H; Miura Y; Amano H; Mochizuki H; Omata M
Hepatol Int; 2019 Mar; 13(2):199-204. PubMed ID: 30671808
[TBL] [Abstract][Full Text] [Related]
77. Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.
Takahashi A; Moriguchi M; Seko Y; Ishikawa H; Yo T; Kimura H; Fujii H; Shima T; Mitsumoto Y; Ishiba H; Takashima H; Nagao Y; Jo M; Arai M; Hara T; Okajima A; Muramatsu A; Morita A; Yoshinami N; Nakajima T; Mitsuyoshi H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y
Anticancer Res; 2019 Sep; 39(9):5149-5156. PubMed ID: 31519627
[TBL] [Abstract][Full Text] [Related]
78. Sorafenib
Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
[TBL] [Abstract][Full Text] [Related]
79. [A case of stage IV gastric cancer with multiple liver metastases surviving for more than 4 years by treatment with chemotherapies without surgery].
Ando T; Suzuki Y; Kanno S; Miyashita E; Tanaka N; Ikezawa F; Shibata C; Sasaki I; Yoshioka T
Gan To Kagaku Ryoho; 2010 May; 37(5):891-4. PubMed ID: 20495322
[TBL] [Abstract][Full Text] [Related]
80. Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps.
Rizzo A; Palmiotti G
Expert Opin Investig Drugs; 2022 Apr; 31(4):331. PubMed ID: 35196947
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
